Shanghai Aohua Photoelectricity Endoscope Co., Ltd. (SHA:688212)
27.20
-0.54 (-1.95%)
At close: Nov 13, 2026
SHA:688212 Revenue
Shanghai Aohua Photoelectricity Endoscope had revenue of 175.30M CNY in the quarter ending September 30, 2026, with 8.02% growth. This brings the company's total for the last twelve months to 806.07M, up 20.02% year-over-year. In the year 2025, Shanghai Aohua Photoelectricity Endoscope had annual revenue of 773.87M with 3.24% growth. That makes Shanghai Aohua Photoelectricity Endoscope the 21,276th largest company in the world by revenue and 3,906th in China.
Revenue (ttm)
806.07M
Revenue Growth
+20.02%
P/S Ratio
4.54
Revenue / Employee
695.48K
Employees
1,121
Market Cap
3.66B
Revenue by Geography
- China 455.50M 59.2%
- Overseas 313.38M 40.8%
Fiscal year ended Dec 31, 2025 See the full SHA:688212 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 773.87M | 24.32M | 3.24% |
| Dec 31, 2024 | 749.55M | 71.47M | 10.54% |
| Dec 31, 2023 | 678.08M | 232.82M | 52.29% |
| Dec 31, 2022 | 445.26M | 98.21M | 28.30% |
| Dec 31, 2021 | 347.05M | 83.77M | 31.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Wuhan Huakang Century Clean Technology | 2.63B |
| Guangdong Biolight Meditech | 1.12B |
| Getein Biotech | 1.11B |
| Zhejiang Orient Gene Biotech | 993.10M |
| Ningbo David Medical Device | 612.67M |
| Hangzhou AGS MedTech | 547.63M |
| Beijing Leadman Biochemistry | 485.94M |
| Contec Medical Systems Co.,Ltd | 477.75M |